Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial.

By K. Brady, T. Pearlstein, G. Asnis, D. Baker, B. Rothbaum, C. Sikes, G. Farfel. Journal of the American Medical Association (JAMA), 2000

678 citations recorded by the source corpus.

Subfields: Applied Psychology, Clinical Psychology, Pharmacology

View Paper: https://www.semanticscholar.org/paper/37c9ebdef3ba67461e41d3fa51ab5157f22e5444

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Applied Psychology

1. A. Mancini
2. Murray B. Stein
3. G. Bonanno
4. Vladan Starcevic
5. A. Masten
6. John T. Jost
7. Fred Luthans
8. D. Fletcher

In Clinical Psychology

1. A. Mancini
2. G. Bonanno
3. Murray B. Stein
4. J. Douglas Bremner
5. Helen S. Mayberg
6. Kate Collie
7. C. Nemeroff
8. Naomi A. Fineberg

In Pharmacology

1. C. Nemeroff
2. Helen S. Mayberg
3. Christine Marcelle Heim
4. Elisabeth B. Binder

Citations in the corpus

• Post-traumatic stress disorder (2015, neutral): “There are potentially hundreds of symptoms, risk factors, resilience factors and personality traits that can impact the onset of PTSD.”
• Beyond Resilience and PTSD: Mapping the Heterogeneity of Responses to Potential Trauma (2012, methodology): “This approach is useful, for example, in treatment efficacy studies (e.g., Brady et al., 2000; Paunovic & öst, 2001) and in studies determining aspects of trauma exposure or other risk factors that promote the development of PTSD symptomatology (e.g., Vogel & Marshall, 2001; Wagner, Heinrichs, &…”
• Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders (2014, result): “Similarly, RCTs with sertraline have yielded both positive [971,972,975,976,978] and negative [973,974,977] results (Level 1, conflicting).”
• Art Therapy for Combat-Related PTSD: Recommendations for Research and Practice (2006, methodology): “…serotonin reuptake inhibitor class, such as sertraline, paroxetine, fluoxetine, fluvoxamine, and citalopram, which have demonstrated effectiveness in both open label and double blind trials (Brady et al., 2000; Marmar et al., 1996; Marshall, Beebe, Oldham, & Zaninelli, 2001; Seedat et al., 2002).”
• Quality-of-life impairment in depressive and anxiety disorders. (2005, background): “(Refer to previously published studies [26–34] for additional details.”
• World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Post-Traumatic Stress Disorders – First Revision (2002, background): “Sertraline was effective in a number of DBPC studies (Brady et al. 2000; Davidson et al. 2001b; Stein et al. 2006; Zohar et al. 2002).”
• Posttraumatic stress disorder: a state-of-the-science review. (2006, result): “However, an early study by Brady et al. (2000) showing that men responded poorly to treatment with sertraline was not confirmed by later studies using larger sample sizes.”